LifeMine Closes Watertown's Largest Funding Round of 2026 and EyePoint's Phase 3 Miss
Plus a flurry of clinical trial updates and quarterly reports
Watertown's First Potential IPO since 2023, Remix's Positive Clinical Trial Results, and Triveni Jumps into the Eczema Market
Plus the initial dosing of Enanta and Avencell's Clinical Trials
What we're looking forward to in 2026
Neumora's positive clinical data , new tenants at the Arsenal, and more
Cultivarium's Next Steps
Stratus Therapeutics winding down, Consider the ALS TDI for Giving Tuesday, and more